Compare Amgen, Inc. (AMGN) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Western Union Co — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while Western Union Co trades at $7.05 (market cap $2.19B). The key difference: Amgen, Inc. is far larger — about 103.1× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.37%). Which is the better fit depends on your goals.
| AMGN | WU | |
|---|---|---|
Market Cap | $225.71B | $2.19B |
Sector | Health | Technology |
52-Week High | $417.20 | $10.28 |
52-Week Low | $271.18 | $6.36 |
Enterprise Value | $269.02B | $2.10B |
Dividend Yield | 2.42% | 13.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
Western Union (WU) trades at $7.08, down 1.12% today, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Valuation ratios appear attractive with a P/E of 5.71 and P/S of 0.56, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company maintains a strong dividend yield, paying $0.24 quarterly, and recently launched Stablecard with Rain to expand digital services.
The outlook is cautious due to earnings volatility and competitive pressures in money transfers. Opportunities include cost management and digital growth, but risks from declining retail performance and high debt levels persist. Analyst consensus is mixed with a $7.14 price target, reflecting uncertainty over turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
